Boost for Axplora’s antibody drug conjugate technology platform

By Jane Byrne

- Last updated on GMT

ADC quality control work at Le Mans site © Axplora
ADC quality control work at Le Mans site © Axplora

Related tags Antibody drug conjugate

The French National Agency for the Safety of Health Products (ANSM) has granted a pharmaceutical establishment license to Axplora’s Le Mans site.

The company said the license is an important milestone for the facility, which is located in northwestern France, continuing its “strong growth”​ in the field of antibody drug conjugates (ADCs).

The site, which has expertise in ADC payloads and bioconjugation, has started providing analytical services for customers enabling the release of ADC drug products, which is aimed at streamlining supply chains, and reducing their analytical burden by eliminating the need to qualify an additional provider of analytical services for the drug product.

A multidisciplinary team including experts in quality assurance, quality control, regulatory affairs, and technical services worked on the preparation and the submission of the application to the ANSM.

"The pharmaceutical establishment license gives us a broader dimension and additional responsibilities in drug development, while continuing to guarantee the quality of our ADC medicines,”​ said Claire Gouverith, global head of quality assurance for Axplora.

Rachel De Luca, Le Mans site director, said: "Our commitment remains the same: to deliver high quality services for ADCs, from payload and bioconjugation to the ADC drug product from early development phases to commercial supply.”

Following the merger of French contract development and manufacturing organization (CDMO), Novasep, and German API maker, PharmaZell, in April this year, all brands of the two companies, including those of PharmaZell’s group unit Farmabios, are consolidated under a newly created corporate umbrella called Axplora.

Sylke Hassel was named CEO of Axplora; the group counts as assets nine manufacturing facilities in Europe and India as well as a research center in the US.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more